Journal
OCULAR IMMUNOLOGY AND INFLAMMATION
Volume 31, Issue 3, Pages 526-535Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/09273948.2022.2039210
Keywords
Phospholipidic high bioavailability curcumin (PHBC); HLA-B27-associated acute anterior uveitis (AAU); Laser Flare Meter (LFM); AAU relapses
Categories
Ask authors/readers for more resources
This study investigated the effectiveness and safety of PHBC in reducing the number and intensity of HLA-B27-related AAU relapses. The results showed that compared to the placebo group, the PHBC group had fewer relapses and a higher proportion of responders, with comparable severity of attacks. Therefore, PHBC treatment may be beneficial.
Background An effective therapy to reduce the number and severity of HLA-B27-related acute anterior uveitis (AAU) recurrences represents a clinical need. Curcumin is a promising therapeutic option in various inflammatory eye diseases. To enhance its absorption and eye tissue selectivity, a phospholipidic-curcumin complex (PHBC) has been formulated (Iphytoone (R), Eye Pharma S.p.A.). Aims This study investigates if PHBC is effective and safe to decrease the number and intensity of HLA-B27-related AAU relapses. Methods HLA-B27-related AAU patients were randomly divided to receive PHBC or placebo for 12 months (NCT03584724). Results Compared with the previous year, the number of relapses decreased in both groups. The proportion of responders was significantly higher in the PBHC group. The severity of attacks was comparable. The study drug was well tolerated. Conclusions A beneficial effect of PHBC treatment is suggested because the proportion of responders was significantly higher in this group of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available